iZafe Group AB (IZAFE.B) AI Stock Analysis

• Market Cap: €251.27M
• Dividend Yield: N/A
• Average Volume (3M): 1.02M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.82
• Revenue Growth: -6.15%
• EPS Growth: 53.72%
• Country: SE
• Employees: 7
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.01
• Shares Outstanding: 364,614,440
• 10 Day Avg. Volume: 1,451,881
• 30 Day Avg. Volume: 1,019,746
• PEG Ratio: 0.06
• Price to Book (P/B): 6.06
• Price to Sales (P/S): 7.41
• P/FCF Ratio: -4.64
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: kr0.50 ▼(-20.63% Downside)

The overall stock score of 54 reflects significant financial challenges faced by iZafe Group AB, with negative profit margins and cash flow issues being major concerns. However, the stock's positive technical indicators provide some optimism, suggesting potential short-term bullish momentum. The valuation remains unattractive due to the negative P/E ratio and lack of dividend yield.

iZafe Group AB Business Overview & Revenue Model

Company Description

iZafe Group AB (IZAFE.B) is a Swedish company operating in the healthcare and technology sectors, specializing in the development and commercialization of digital health solutions. The company primarily focuses on enhancing medication management and adherence through innovative products and services, including smart medication dispensers and related software applications designed to improve patient outcomes and streamline healthcare processes.

How the Company Makes Money

iZafe Group AB generates revenue through the sale of its digital health products, particularly its smart medication dispensers. The company employs a subscription-based model for its software services, allowing healthcare providers and patients to access ongoing support and updates. Additionally, iZafe may partner with healthcare facilities and organizations to implement its solutions, which can lead to revenue from service agreements and collaborations. Key revenue streams include direct product sales, subscription fees from software usage, and potential licensing agreements with third-party developers or healthcare systems.

iZafe Group AB Financial Statement Overview

Summary

iZafe Group AB is facing significant financial challenges with negative profit margins, consistent losses, and declining cash flows. Despite a positive revenue growth rate, the company needs to address profitability and cash flow issues to ensure long-term sustainability. The balance sheet is relatively stable, but improvements in operational efficiency and strategic financial management are crucial.

Income Statement

iZafe Group AB's income statement reveals significant challenges. The company has a negative gross profit margin and net profit margin, indicating that it is not currently profitable. Despite a positive revenue growth rate of 16.51% TTM, the company continues to face substantial losses with negative EBIT and EBITDA margins. These factors suggest ongoing operational difficulties and a need for strategic improvements to achieve profitability.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio of 0.55 TTM, indicating manageable leverage. However, the return on equity is negative, reflecting the company's inability to generate profits from shareholders' equity. The equity ratio is relatively healthy, suggesting a stable asset base, but the negative ROE highlights the need for improved financial performance.

Cash Flow

Cash flow analysis indicates negative operating and free cash flows, with a declining free cash flow growth rate of -17.11% TTM. The operating cash flow to net income ratio is negative, showing that the company is not generating sufficient cash from its operations to cover its losses. The free cash flow to net income ratio is 1.0, suggesting that all free cash flow is being used to cover net losses, which is unsustainable in the long term.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.83M	7.95M	1.82M	729.00K	442.00K	8.90M
Gross Profit	-654.00K	-1.63M	293.00K	123.00K	-1.14M	7.64M
EBITDA	-13.71M	-15.49M	-15.62M	-21.94M	-32.35M	-10.67M
Net Income	-19.14M	-20.51M	-32.17M	-23.53M	-36.27M	-12.75M
Balance Sheet
Total Assets	20.64M	24.23M	34.61M	50.70M	48.43M	35.08M
Cash, Cash Equivalents and Short-Term Investments	825.00K	2.15M	5.83M	1.70M	18.73M	2.55M
Total Debt	5.73M	6.58M	2.52M	4.00M	4.98M	750.00K
Total Liabilities	10.29M	14.50M	9.26M	11.74M	7.70M	5.62M
Stockholders Equity	10.34M	9.73M	25.35M	38.96M	40.73M	29.46M
Cash Flow
Free Cash Flow	-11.82M	-12.72M	-12.71M	-24.12M	-33.71M	-26.14M
Operating Cash Flow	-11.82M	-11.70M	-11.26M	-21.46M	-33.49M	-24.57M
Investing Cash Flow	-756.00K	-1.02M	-1.46M	-2.51M	-214.00K	19.04M
Financing Cash Flow	12.18M	8.69M	16.85M	6.94M	49.88M	604.00K

iZafe Group AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.63
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IZAFE.B, the sentiment is Positive. The current price of 0.63 is below the 20-day moving average (MA) of 0.67, above the 50-day MA of 0.57, and above the 200-day MA of 0.35, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 48.58 is Neutral, neither overbought nor oversold. The STOCH value of 20.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:IZAFE.B.

iZafe Group AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IZAFE.B	54 Neutral	€251.27M	-11.88	-109.88%	―	-6.15%	53.72%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NXTCL	47 Neutral	kr82.76M	―	-52.45%	―	2.56%	52.76%
SPAGO	38 Underperform	kr71.45M	―	-106.95%	―	-48.15%	51.95%
ICO	38 Underperform	kr93.39M	-1.10	―	―	-45.59%	37.79%
BIOSGN	34 Underperform	kr111.31M	―	-101.53%	―	―	65.16%